Physician profile
Thomas J Mclaughlin
NPI 1518062827
$5,253.66
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,080 · 2020: $1,889 · 2021: $215 · 2022: $70.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,064.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $981.65 | 2019-2021 | |
| Allergan, INC. | $625.26 | 2019-2020 | |
| Alkermes, INC. | $484.26 | 2019-2020 | |
| Shire North American Group INC | $289.72 | 2019 | |
| Lundbeck LLC | $286.94 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $237.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.25 | 2020-2021 | |
| Neos Therapeutics, Lp | $178.18 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $173.79 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $164.11 | 2019 | |
| Sunovion Pharmaceuticals INC. | $141.03 | 2019 | |
| Abbvie INC. | $90.24 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $72.62 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $68.07 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $55.09 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $43.42 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.48 | 2020 | |
| Orexo US, INC. | $26.30 | 2020 | |
| Eisai INC. | $16.19 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.